This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Summary of interventions for peptic ulcer disease (NICE)

Authoring team

Summary of Interventions for peptic ulcer disease

  • H pylori eradication therapy should be offered to people who have tested positive for H pylori and who have peptic ulcer disease
  • for people using NSAIDs with diagnosed peptic ulcer, stop the use of NSAIDs where possible. Offer full-dose PPI (table 1) or H2RA therapy for 8 weeks and, if H pylori is present, subsequently offer eradication therapy
  • if peptic ulcer (gastric or duodenal) and H pylori then offer retesting for H pylori 6 to 8 weeks after beginning treatment, depending on the size of the lesion
  • full-dose PPI (table 1) or H2RA therapy for 4 to 8 weeks should be offered to people who have tested negative for H pylori who are not taking NSAIDs
  • for people continuing to take NSAIDs after a peptic ulcer has healed, discuss the potential harm from NSAID treatment. Review the need for NSAID use regularly (at least every 6 months) and offer a trial of use on a limited, 'as required' basis. The clinician should consider reducing the dose, substituting an NSAID with paracetamol, or using an alternative analgesic or low-dose ibuprofen (1.2 g daily)
  • if a person at high risk (previous ulceration) and for whom NSAID continuation is necessary, offer gastric protection or consider substitution with a cyclooxygenase (COX)-2-selective NSAID
  • if unhealed ulcer then
    • exclude non-adherence, malignancy, failure to detect H pylori, inadvertent NSAID use, other ulcer-inducing medication and rare causes such as Zollinger-Ellison syndrome or Crohn's disease
  • if symptoms recur after initial treatment, offer a PPI to be taken at the lowest dose possible to control symptoms. Discuss using the treatment on an 'as required' basis with people to manage their own symptoms

Table 1: PPI doses

PPI

Full/Standard dose

Low dose (on demand dose)

Double dose

Esomeprazole

20 mg* once a day

Not available

40 mg*** once a day

Lansoprazole

30mg once a day

15mg per day

30 mg** twice a day

Omeprazole

20 mg once a day

10mg* per day

40 mg once a day

Pantoprazole

40 mg once a day

20mg per day

40mg twice a day

Rabeprazole

20mg once a day

10mg per day

20mg twice a day

* lower than the licensed starting dose for esomeprazole in GORD, which is 40 mg, but considered to be dose-equivalent to other PPIs. When undertaking meta-analysis of doserelated effects, NICE classed esomeprazole 20 mg as a full-dose equivalent to omeprazole 20 mg.

**off-label dose for GORD

***40 mg is recommended as a double dose of esomeprazole because the 20-mg dose is considered equivalent to omeprazole 20 mg.

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.